Valuation: Geron Corporation

Market Cap 623M 565M 522M 471M 888M 58.74B 919M 6.27B 2.49B 31.38B 2.34B 2.29B 99.6B P/E 2026 *
-43x
P/E 2027 * 10.3x
Enterprise Value 623M 565M 522M 471M 888M 58.74B 919M 6.27B 2.49B 31.38B 2.34B 2.29B 99.6B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 1.84x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.72%
1 week-2.30%
Current month+8.12%
1 month-18.74%
3 months-34.22%
6 months-30.93%
Current year-26.74%
1 week 0.94
Extreme 0.9412
1.02
1 month 0.84
Extreme 0.84
1.24
Current year 0.84
Extreme 0.84
2.01
1 year 0.84
Extreme 0.84
2.01
3 years 0.84
Extreme 0.84
5.34
5 years 0.84
Extreme 0.84
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 55 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Free

Director

6,351 0.0010%
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-2.72%-2.30%-13.66%-49.37% 623M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.82%+0.51%+31.74%+157.19% 41B
Weighted average by Cap. -0.83%+0.21%+36.55%+154.94%

Financials

2026 *2027 *
Net sales 235M 213M 197M 178M 335M 22.19B 347M 2.37B 940M 11.85B 883M 864M 37.62B 338M 306M 283M 256M 482M 31.88B 499M 3.4B 1.35B 17.03B 1.27B 1.24B 54.05B
Net income -14.25M -12.92M -11.95M -10.78M -20.32M -1.34B -21.03M -144M -56.91M -718M -53.49M -52.36M -2.28B 62.34M 56.49M 52.25M 47.14M 88.84M 5.88B 91.97M 628M 249M 3.14B 234M 229M 9.97B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
13/11/26 USD 0.9670 -2.72% 7,099,034
12/11/26 USD 0.9940 -2.55% 10,354,729
11/11/26 USD 1.020 +4.70% 6,557,621
10/11/26 USD 0.9742 -2.24% 12,511,393
09/11/26 USD 0.9965 +0.68% 5,732,297
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.9670USD
Average target price
3.500USD
Spread / Average Target
+261.94%
  1. Stock Market
  2. Stocks
  3. GERN Stock